Ai Centrum Medyczne Sp. z o.o.
- Address
- lock Available on a paid plan
Immune System Diseases
At Ai Centrum Medyczne Sp. z o.o. in Poznan, clinical research in immune system diseases focuses on improving care for conditions such as psoriatic arthritis, rheumatoid arthritis, Sjögren's disease, and systemic lupus erythematosus. These studies are designed to evaluate new therapies, compare treatment options, and better understand long-term safety and effectiveness.
- Testing targeted treatments for active psoriatic arthritis and related inflammatory joint disease
- Evaluating treatment effectiveness in rheumatoid arthritis and moderate to severe rheumatoid arthritis
- Assessing new options for Sjögren's disease and systemic lupus erythematosus
These trials reflect a strong interest in autoimmune conditions, with attention to symptom control, safety, and longer-term patient outcomes.
Musculoskeletal Diseases
Research in musculoskeletal diseases at this site includes studies of psoriatic arthritis and rheumatoid arthritis, two chronic conditions that can cause pain, stiffness, and joint damage. The trials are comparing emerging therapies and reference treatments to see how well they reduce disease activity and support better daily function.
- Comparing new treatment approaches for active psoriatic arthritis
- Studying effectiveness in moderate to severe rheumatoid arthritis
- Exploring options for patients who have not responded well to earlier therapies
The work in this therapeutic area is centered on finding more effective and better-tolerated ways to manage inflammatory joint disease.
Skin and Connective Tissue Diseases
Clinical trials in skin and connective tissue diseases at Ai Centrum Medyczne Sp. z o.o. include studies in moderate to severe plaque psoriasis and related immune-mediated conditions. The research aims to assess how well newer treatments control symptoms, while also monitoring safety and long-term tolerability.
- Evaluating therapies for moderate to severe plaque psoriasis
- Studying immune-related skin and tissue inflammation
- Assessing the safety of longer-term treatment use
This area highlights a broader effort to improve care for chronic inflammatory skin disease through more precise and durable treatment strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Eli Lilly & Co.1active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ai Centrum Medyczne Sp. z o.o.
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis | Acelyrin Inc. | Phase IV | Not Recruiting | Apr 2023 | Oct 2024 |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Tildrakizumab | 3 | Unknown | 2021-01-15 | 2023-04-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.